Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Has Average Target Price of $33.65

by · The Markets Daily

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Free Report) has been assigned an average rating of “Hold” from the twenty-two brokerages that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $33.65.

RARE has been the subject of a number of research reports. Robert W. Baird lowered shares of Ultragenyx Pharmaceutical from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $40.00 to $16.00 in a research note on Thursday, September 3rd. Wall Street Zen upgraded Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Wedbush dropped their price target on Ultragenyx Pharmaceutical from $30.00 to $23.00 and set a “neutral” rating on the stock in a research note on Thursday, September 3rd. Barclays lifted their price objective on Ultragenyx Pharmaceutical from $32.00 to $35.00 and gave the stock an “overweight” rating in a report on Monday, September 21st. Finally, Cantor Fitzgerald upped their price objective on Ultragenyx Pharmaceutical from $33.00 to $39.00 and gave the company an “overweight” rating in a research report on Friday, September 18th.

Get Our Latest Stock Report on Ultragenyx Pharmaceutical

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,066 shares of the firm’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $15.27, for a total value of $107,897.82. Following the transaction, the chief financial officer directly owned 89,229 shares of the company’s stock, valued at approximately $1,362,526.83. This trade represents a 7.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 8,510 shares of company stock valued at $127,561 over the last 90 days. Company insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Hedge funds and other institutional investors have recently made changes to their positions in the business. Sterling Capital Management LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 102.4% in the third quarter. Sterling Capital Management LLC now owns 2,475 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 1,252 shares during the last quarter. Pinnacle Associates Ltd. grew its position in Ultragenyx Pharmaceutical by 16.6% during the third quarter. Pinnacle Associates Ltd. now owns 152,925 shares of the biopharmaceutical company’s stock valued at $2,298,000 after buying an additional 21,821 shares during the period. Assenagon Asset Management S.A. increased its holdings in Ultragenyx Pharmaceutical by 295.4% during the third quarter. Assenagon Asset Management S.A. now owns 477,869 shares of the biopharmaceutical company’s stock valued at $7,182,000 after buying an additional 357,005 shares during the last quarter. Versant Capital Management Inc increased its holdings in Ultragenyx Pharmaceutical by 121.9% during the third quarter. Versant Capital Management Inc now owns 2,556 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 1,404 shares during the last quarter. Finally, Integrated Wealth Concepts LLC purchased a new stake in Ultragenyx Pharmaceutical during the second quarter valued at approximately $311,000. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Price Performance

Shares of RARE stock opened at $15.65 on Wednesday. The company has a 50 day moving average price of $17.72 and a 200-day moving average price of $23.36. Ultragenyx Pharmaceutical has a 52 week low of $12.73 and a 52 week high of $39.89. The firm has a market capitalization of $1.54 billion, a PE ratio of -2.68 and a beta of 0.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.32. The company had revenue of $214.00 million for the quarter, compared to the consensus estimate of $183.08 million. During the same quarter last year, the company earned ($1.17) EPS. The firm’s revenue for the quarter was up 28.5% on a year-over-year basis. Analysts anticipate that Ultragenyx Pharmaceutical will post -3.91 earnings per share for the current year.

About Ultragenyx Pharmaceutical

(Get Free Report)

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company concentrates on conditions with significant unmet medical needs, including genetic, metabolic and endocrine disorders, and uses biologics, small molecules and gene therapy approaches in its research and development programs.

Ultragenyx’s commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), a therapy for long-chain fatty acid oxidation disorders.

See Also